Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer
The First Hospital of Jilin University
The First Hospital of Jilin University
Coherent Biopharma (Hefei) Co., Ltd.
Centre Leon Berard
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Region Stockholm
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Institut Paoli-Calmettes
Institut Cancerologie de l'Ouest
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
N.N. Petrov National Medical Research Center of Oncology
University of Strathclyde
The First Affiliated Hospital with Nanjing Medical University
Gazi University
Centre Hospitalier Universitaire Vaudois
Cairo University
Eunseong Medical Foundation Good GANG-AN HOSPITAL
Marmara University
Universitat Jaume I
Georgetown University
RemeGen Co., Ltd.
Ciusss de L'Est de l'Île de Montréal
Universitair Ziekenhuis Brussel
Thomas Jefferson University
Kaiser Permanente
Centre Georges Francois Leclerc
Centre Leon Berard
National Cancer Centre, Singapore
Ataturk University
Icahn School of Medicine at Mount Sinai
RemeGen Co., Ltd.
University Hospital, Ghent
Fudan University
Shengjing Hospital
Massachusetts General Hospital
Peking Union Medical College Hospital
University Hospital, Ghent
The Greater Poland Cancer Centre
Peking Union Medical College Hospital
Peking Union Medical College Hospital
Hospital Clinic of Barcelona
Uppsala University
Academic and Community Cancer Research United
Fondation Hôpital Saint-Joseph
Lund University
Changchun GeneScience Pharmaceutical Co., Ltd.
Universidad de Granada
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Chung Shan Medical University
Uppsala University Hospital
University Medical Center Groningen